Literature DB >> 10966074

Luminacins: a family of capillary tube formation inhibitors from Streptomyces sp. II. Biological activities.

T Wakabayashi1, R Kageyama-Kawase, N Naruse, Y Funahashi, K Yoshimatsu.   

Abstract

Twelve of the fourteen isolated components of the luminacin family were assayed for activity to inhibit capillary tube formation in vitro. Seven of them showed potent activity with IC50 values of less than 0.1 microg/ml in a rat aorta matrix culture model. Luminacin D, the strongest inhibitor, inhibited both endothelial cell proliferation and capillary tube formation. Morphological observation suggested that luminacin D inhibited the rearrangement of endothelial cells in the initial stage of tube formation. Luminacins and their derivatives are good candidates for application as angiogenesis inhibitors with a novel mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966074     DOI: 10.7164/antibiotics.53.591

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  4 in total

1.  Total synthesis of luminacin D.

Authors:  J Brad Shotwell; Evan S Krygowski; John Hines; Brian Koh; Elliott W D Huntsman; Hui Won Choi; John S Schneekloth; John L Wood; Craig M Crews
Journal:  Org Lett       Date:  2002-09-05       Impact factor: 6.005

2.  Anti-cancer Effect of Luminacin, a Marine Microbial Extract, in Head and Neck Squamous Cell Carcinoma Progression via Autophagic Cell Death.

Authors:  Yoo Seob Shin; Hyun Young Cha; Bok-Soon Lee; Sung Un Kang; Hye Sook Hwang; Hak Cheol Kwon; Chul-Ho Kim; Eun Chang Choi
Journal:  Cancer Res Treat       Date:  2015-09-09       Impact factor: 4.679

3.  Inhibition of IGF-1-Mediated Cellular Migration and Invasion by Migracin A in Ovarian Clear Cell Carcinoma Cells.

Authors:  Tamami Ukaji; Yinzhi Lin; Kouji Banno; Shoshiro Okada; Kazuo Umezawa
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

Review 4.  Blue-Print Autophagy in 2020: A Critical Review.

Authors:  Sergey A Dyshlovoy
Journal:  Mar Drugs       Date:  2020-09-21       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.